Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Capital Expenditures (2016 - 2025)

Dexcom (DXCM) has disclosed Capital Expenditures for 16 consecutive years, with $101.9 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 18.22% to $101.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $363.5 million through Dec 2025, up 1.31% year-over-year, with the annual reading at $363.5 million for FY2025, 1.31% up from the prior year.
  • Capital Expenditures for Q4 2025 was $101.9 million at Dexcom, up from $80.5 million in the prior quarter.
  • The five-year high for Capital Expenditures was $124.6 million in Q4 2024, with the low at $50.4 million in Q3 2023.
  • Average Capital Expenditures over 5 years is $85.6 million, with a median of $89.2 million recorded in 2022.
  • The sharpest move saw Capital Expenditures skyrocketed 200.3% in 2021, then plummeted 53.42% in 2023.
  • Over 5 years, Capital Expenditures stood at $80.2 million in 2021, then dropped by 20.82% to $63.5 million in 2022, then dropped by 17.32% to $52.5 million in 2023, then surged by 137.33% to $124.6 million in 2024, then fell by 18.22% to $101.9 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $101.9 million, $80.5 million, and $94.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.